Mindmed and liechti lab in basel switzerland publish first pharmacogenetic data on lsd to help guide personalized dosing

New york, may 26, 2021 /prnewswire/ -- mindmed (nasdaq: mnmd) (neo: mmed) (de: mmq), a leading psychedelic medicine biotech company, announced today the publication of the first pharmacogenetic data on lsd to help personalize dosing. the study results from a pooled secondary analysis of four phase 1 studies that each used a randomized, double-blind, placebo-controlled, crossover design and were conducted at the university hospital basel liechti lab, in basel, switzerland.
MNMD Ratings Summary
MNMD Quant Ranking